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Background: Pancreatic cancer is the third most common cancer related cause of death. Even in the 15% of
patients who are eligible for surgical resection the outlook is dismal with less than 10% of patients surviving after
5 years. Allogeneic hematopoietic (allo-HSCT) stem cell transplantation is an established treatment capable of to
providing cure in a variety of hematopoietic malignancies. Best results are achieved when the underlying neoplasm
has been turned into a stage of minimal disease by chemotherapy. Allo-HSCT in advanced solid tumors including
pancreatic cancer have been of limited success, however studies of allo-HSCT in solid tumors in minimal disease
situations have never been performed. The aim of this trial is to provide evidence for the clinical value of allo-HSCT
in pancreatic cancer put into a minimal disease status by effective surgical resection and standard adjuvant
chemotherapy.
Methods/Design: The STEM PACE trial is a single center, phase II study to evaluate adjuvant allogeneic
hematopoietic stem cell transplantation in pancreatic cancer after surgical resection. The study will evaluate as
primary endpoint 2 year progression free survival and will generate first time state-of-the-art scientific clinical
evidence if allo-HSCT is feasible and if it can provide long term disease control in patients with effectively resected
pancreatic cancer. Screened eligible patients after surgical resection and standard adjuvant chemotherapy with HLA
matched related stem cell donor can participate. Patients without a matched donor will be used as a historical
control. Study patients will undergo standard conditioning for allo-HSCT followed by transplantation of allogeneic
unmanipulated peripheral blood stem cells. The follow up of the patients will continue for 2 years. Secondary
endpoints will be evaluated on 7 postintervention visits.
Discussion: The principal question addressed in this trial is whether allo-HSCT can change the unfavourable natural
course of this disease. The underlying hypothesis is that allo-HSCT has the capacity to provide long-term disease
control to an extent otherwise not possible in pancreatic cancer, thereby substantially improving survival of affected
patients.
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Table 1 Negative and positive predictors for overall
survival in patients undergoing pancreatic resection
according to Hartwig et al [14]





Age >70 years G1 tumor grading
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Rationale
Pancreatic cancer is one of the major causes of cancer
death globally, with a 5-year survival rate of less than 5%
[1]. In the western world pancreatic cancer is the third
most common cancer related cause of death. Even though
substantial research was conducted in the last decades, to
the current date, surgical resection is the only effective
therapy that offers significant survival prolongation and
potential cure of patients with pancreatic cancer. The out-
look of patients who undergo surgical resection is better
and specialized centers can achieve a resection rate of
about 15% [2]. Although surgical resection cannot guar-
antee a cure, 5-year survival is improved to around 10%
after resection [2]. Therefore an obvious need exists to
improve the long-term survival in pancreatic cancer pa-
tients even in patients resected with curative intent.
While it remains unclear if there is a survival benefit of
adjuvant chemoradiotherapy with or without mainten-
ance chemotherapy [3-6], there is a survival benefit for
adjuvant chemotherapy [5,7-11].
Whereas overall survival of patients with ductal
adenocarcinoma remains generally low, some patients
with long-term survival and improved prognosis have
been identified previously [2,12]. Prognosis of patients
with pancreatic adenocarcinoma is defined and was
later validated by tumor stages according to the AJCC
Cancer Staging Manual [13]. In patients with resected
pancreatic adenocarcinoma prognostic factors were re-
cently defined in a cohort of patient undergoing a highly
standardized surgical strategy [14]. In this study tumor
size, nodal status and distant metastasis were confirmed
as independent predictors of survival in patients who
underwent resection. Additional independent negative
prognostic parameters were identified in our patient
cohort being age >70 years, preoperative presence of
insulin-dependent diabetes mellitus, serum CA-19-9
levels above 400 U/ml, G3/4 tumor grading and a lymph
node ratio (LNR) >0.2 [14]. Also, the revised R1 resec-
tion classification was an independent predictive marker
[14]. G1 tumor grading was identified as positive risk
factor [14] (Table 1).
Using this prognostic risk score (“Hartwig Score”), the
survival between prognostic groups can be further dis-
criminated additionally to the AJCC staging system, iden-
tifying 4 risk groups with 5-year survival rates of 0%, 6.6%,
17.4% and 54.6% from the highest to the lowest risk group.
This risk grouped analysis provided additional information
especially for the largely heterogeneous group of AJCC
stage II patients.
Altogether, this still indicates that there is a clear need
to improve the long-term survival in pancreatic cancer pa-
tients in high risk groups (group 1–3) even in curatively
resected patients asking for novel treatment strategies.Allogeneic hematopoietic stem cell transplantation in
solid tumors
As the field of cancer immunology has grown, a deeper
understanding of the immune system’s recognition of
tumor cells and their antigens has translated into exciting
new treatments for a variety of solid tumors including
pancreatic cancer. The main function of the human im-
mune system lies in the identification and elimination of
pathogenic organisms such as bacteria and viruses but also
of the body’s own defective cells, such as tumor cells.
During cancer development, e.g. pancreatic cancer, the
immune system apparently fails to identify and reject
those tumor cells. To activate the partially “blind” im-
mune system of cancer patients to fight against the
tumor has been a goal in cancer research for decades. In
this study we aim to exchange the unresponsive immune
system with a new, tumor-sensitive immune system by
allogeneic hematopoietic stem cell transplantation (allo-
HSCT).
Transplantation of allogeneic hematopoietic stem cells
from a human-leukocyte-antigen (HLA)-compatible donor
is an established treatment for relapsed and high-risk
hematological malignancies [15]. Allogeneic transplantation
in hematological neoplasms can provide eradication of
disease by a donor T-cell mediated immune graft-versus-
tumor (GvT) effect, which also may be effective in solid
tumors [16].
Allo-HSCT for a solid tumor was initially published
for a patient with breast cancer [17]. To date, several
series of allogeneic transplants in solid tumors have been
published aiming at exploiting the GvT effect especially
in breast and in renal cancer [18]. These concepts have
been complemented with the development of nonmye-
loablative (reduced intensity) allogeneic transplantation
with or without the use of donor lymphocyte infusions
(DLI) to avoid the high treatment related mortality and
morbidity associated with the use of conventional mye-
loablative conditioning regimens [18]. Currently more
than 1000 patients with refractory or other advanced
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Complete or partial responses have been achieved in pa-
tients with several types of solid tumors, including renal
cell [19-23], breast [22-25], ovarian [23], colon [19,26,27]
and also pancreatic cancers [28-31].
There are several lines of evidence that GvT effects are
effective in solid tumors. It was shown that survival in
patients with solid cancer was significantly improved in
patients with chronic GVHD, suggesting GvT activity
[23]. In a study in renal cancer, chronic GVHD and DLI
were associated with improved survival [32]. Additionally
DLI efficacy was observed after allo-HSCT for breast can-
cer [22-25]. Regression of renal cancer after allo-HSCT
was correlated with the emergence of tumor antigen-
reactive T cells [33], and the expansion of tumor-
specific T cells could be demonstrated in patients who
responded after GVHD onset following allo-HSCT for
colon carcinoma [19,26,27].Allo-HSCT in pancreatic cancer
Although pancreatic cancer was originally thought to be
poorly immunogenic, recent data have challenged this
presumption. First, a high incidence of tumor-specific T
lymphocytes is seen in bone marrows of patients with
pancreatic cancer [34]. Second, Fukunaga et al. [35] ana-
lyzed 80 surgically resected pancreatic cancer tumors
looking specifically for CD4+ T cells, CD8+ T cells, and
dendritic cells within the tumor [35]. They reported that
higher levels of CD4+ and CD8+ tumor-infiltrating lym-
phocytes in pancreatic cancers were associated with longer
overall survival after surgical resection. The presence of
both CD4+ and CD8+ tumor-infiltrating lymphocytes was
an independent favorable prognostic factor in a multivari-
ate analysis [35]. These data, together with results from
early immunotherapy clinical trials, support the hypothesis
that pancreatic cancer is treatable by an antitumor im-
mune response. In this regard, Omuro et al. reported a
marked regression of a large pancreatic tumor following
allogeneic transplantation, which was attributed to GvT
effects due to complete T-cell chimerism before tumor re-
gression [31]. Recently, Abe et al. evaluated 5 patients with
advanced pancreatic cancer who received allo-HSCT [28].
In these patients complete donor chimerism was obtained
in 3 out of 5 patients. Antitumor effects considered to be
GVT-mediated were observed in 2 of 5 patients.Limitations of allo-HSCT in solid tumors
However, in contrast to hematopoietic malignancies,
complete and durable regressions of solid tumors have
been observed only very rarely after allo-HSCT. This
could be due to genuine biological differences between
hematopoietic and epithelial tumor cells, such as expres-
sion of HLA-class-II or minor histocompatibility antigens[36], or the protective effect of tumor stroma regularly
present in formations of solid tumor cells [36].
Apart from these biological considerations one obvious
reason for the yet overall disappointing results of allo-
HSCT for solid tumors could be the fact that almost all
published studies have been performed in patients with
advanced disease characterized by bulky/metastatic and
actively proliferative tumor masses. It is well known from
multiple studies in hematopoietic malignancies that the
probability of effective GvT-mediated disease control after
allo-HSCT is strongly correlated with tumor mass and
proliferation at the time of transplant [36-38]. Thus,
allo-HSCT may be much more effective if performed in
a situation of temporarily controlled minimal residual
disease. Notably, tumor mass and proliferation activity
were found to be a strong survival predictor in studies
on allo-HSCT for solid tumors [23,32].
Rationale for a trial on allo-HSCT in pancreatic carcinoma
in a MRD setting
Thus, the hypothesis underlying this trial is that the GvT
activity conferred with allo-HSCT could result in complete
eradication of pancreatic adenocarcinoma if applied in a
setting of minimal residual disease achieved by radical re-
section of the primary tumor, thereby curing the disease.
This is based on the following considerations:
 There is a large body of pre-clinical and clinical
evidence that GvT can be effective in solid tumors
including pancreatic cancer;
 In solid tumors, factors protecting tumor cells from
GvT activity, such as an unfavorable effector-target
cell ratios, immunosuppressive effects derived from
large tumor masses, and a protective stromal
environment, could be circumvented by applying
allo-HSCT in an MRD setting;
 Broad and reproducible evidence from
allotransplants in hematopoietic malignancies shows
that allo-HSCT is indeed much more capable of
providing durable disease control if performed in an
MRD setting than in the presence of bulky and
uncontrolled tumor masses.
Objectives
The overall objective of this trial is to generate for the
first time state-of-the-art scientific clinical evidence
that allo-HSCT can provide long-term disease control
in patients with radically resected pancreatic ductal
adenocarcinoma and may have the potential to change
the natural course of this otherwise fatal malignancy.
Specifically, the study aims at demonstrating that
allo-HSCT is feasible in patients with radically resected
pancreatic adenocarcinoma, and at exploring if the
immunotherapeutic activity conferred with allo-HSCT
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residual carcinoma persisting after surgical resection.
Methods/Design
Trial location
The trial will be performed at a single site located at the
University Hospital Heidelberg, Germany. All patients
will be operated at the Department of General, Visceral
and Transplanation Surgery, and allo-HSCT will be per-
formed at the Department of Internal Medicine V.
Study design
This is a single-arm, open phase II trial comparing
the study data to historical controls. Sponsor of the
trial according to the GCP [39] guidelines and the
German AMG regulations is the University Hospital
Heidelberg.
The duration of intervention per patient will be 5 weeks.
On protocol follow-up time per patient is 2 years after
surgical resection.
Surgical resection and adjuvant chemotherapeutic
treatment prior to study intervention (i.e. allo-HSCT)
will follow accepted standards but is not part of the
protocol.
Trial population and eligibility criteria
Candidate patients have successfully undergone standard
surgical treatment for pancreatic cancer followed by
accomplishment of standard adjuvant chemotherapy.
Patients, who have one or more full siblings, will be
screened for eligibility at the Department of General,
Visceral and Transplantation Surgery before discharge
from hospitalization for tumor resection. Screening will be
documented on the screening log, but screening results
will be documented on CRF only if the patient is subse-
quently registered.
Inclusion criteria
 Histologically proven diagnosis of pancreatic ductal
adenocarcinoma having undergone radical resection
(R1/R0 local resection) within the last 4–6 months
at the University Hospital Heidelberg
 Hartwig score 1 or 2 (Hartwig et al. [14])
 Measurable tumor serum marker (i.e. CA 19–9)
prior to resection
 Age at registration 18 to 65 years
 Karnofsky index > /= 70
 Hematopoietic cell transplantation comorbidity
index (HCT-CI) score 0–1 (pancreatic carcinoma
does not count against the score)
 HLA-identical (10/10 intermediate-resolution) related
donor
 Written informed consent, signed and datedExclusion criteria
 Hartwig score ≤ 0 (Hartwig et al. [14])
 HIV, HBV, HCV seropositivity
 Organ dysfunction– Symptomatic coronary artery disease or ejection
fraction <35%
– DLCO ≤60%, FEV1 < 65% of predicted FEV1
despite appropriate treatment or receiving
supplementary continuous oxygen
– Liver function abnormalities: Patients with will be
excluded if total serum bilirubin >1.5 X ULN, or
AST/ALT >2.5XULN
– Chronic renal dysfunction defined by a creatinine
clearance <50 ml/min.
 Fertile men and women unwilling to use
contraceptive techniques during and for 12 months
following treatment
 Females who are pregnant or breastfeeding
 Active other malignancies and/or a history of
another malignancy treated by chemotherapy or
radiotherapy within the last five years prior to
inclusion
 Patients with systemic, uncontrolled infections
 Current alcohol or drug abuse
 Previously known contraindication and/or
intolerance against study-related substances
including medication for immunosuppression
 Inability to understand the scope of the study and
intent of treatment. Dementia or altered mental
status that would prohibit understanding informed
consent
 Participation in another interventional clinical trial
according to the German Pharmaceuticals Act
(AMG) within 30 days prior to inclusion
Gender consideration
The distribution of female and male patients is not
relevant for the study as both gender are affected by
pancreatic adenocarcinoma and treatment effects are
not different in both groups.
Recruitment and trial timeline
The duration of the trial for each subject is expected to be
24 months (one month study intervention and 23 months
follow-up). The overall duration of the trial is expected
to be approximately 45 months. Recruitment of subjects
will start in April 2013. The actual overall duration or
recruitment may vary and is estimated to be completed
in September 2014.
Sample size and statistical consideration
The trial will include 12 patients undergoing the study
intervention. Patients who were registered on the basis
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allo-HSCT because of donor ineligibility, refusal, disease
progression, comorbidity or interim ineligibility accord-
ing to the inclusion/exclusion criteria will be replaced
and will not be counted against the accrual target of 12
patients.
For safety reasons, patients will be enrolled in a 3 + 3 + 6
sequence: After registration of the first 3 patients, en-
rolment will be interrupted until the review of 100-day
NRM and SAE reported for these 3 patients by the Data
Monitoring and Safety Committee (DMSC) has con-
firmed safety thus justifying continuation of the trial. A
similar procedure is repeated after the next 3 patients
accrued, and before the remaining 6 patients can be en-
rolled. The 100-day NRM for this trial is anticipated to
be 20% or less, calculated on the basis of all 12 patients
to be included.
The trial is designed to explore the feasibility of the in-
vestigated therapy. If the results of this study indicate
feasibility, it will serve as a basis for larger randomized
protocols for proving efficacy. As no formal statistical
hypotheses are defined, the analysis is performed by
methods of descriptive data analysis, and therefore, no
formal sample size calculation is performed.
Investigational plan
Screening and pre-information
A simplified flow sheet of the trial can be found in Figure 1.
Candidate patients will have successfully undergone stand-
ard surgical treatment for pancreatic cancer followed byFigure 1 Simplified study investigational plan.accomplishment of standard adjuvant chemotherapy, and
who have one or more full siblings, will be screened for
eligibility. During the screening procedure, the patient will
be concisely informed about the possibility of participating
in the trial and its purpose, principle, risks, and chances.
He/she will be explained that a prerequisite for participa-
tion is the need for donor search, and that registration
with the trial is possible only if a matched related donor is
found. The patient will be informed that probability of
meeting this criterion is 25% per sibling.
Patients willing to initiate donor search have to confirm
their consent to this in written form.Donor search
Sibling donor search will be initiated immediately after
signing the informed consent form by the patient. Sib-
lings will be contacted by standard procedures, provided
with written information briefly describing the trial and
the need to obtain a blood sample from them, which is
to be submitted along with the written and undersigned
consent form for HLA-typing to the Coordination of-
fice. HLA-A, B, C, DRB1, and DQB1 typing is to be
performed using DNA-based methods. To be eligible
for inclusion, patients and related donors have to be
HLA-identical (10/10 intermediate-resolution). A matched
related donor may not have any a priori contraindica-
tions and a donor written informed consent will be ob-
tained by an independent investigator to avoid conflicts
of interest.
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Once the patient has completed 12–20 weeks of adju-
vant chemotherapy without disease progression and
has a matched related stem cell donor available, he/
she will undergo routine follow-up assessment. Prior
to registration, eligible patients will be provided with
information in comprehensible terms about radically
resected pancreatic ductal adenocarcinoma and the
current status of knowledge about treatment of this
disease and on the aims of the study, and about the
possibility to participate in the present trial. It will
be explained to the patient that once she/he has
started conditioning chemotherapy for allo-HSCT,
any refusal of subsequent parts of the study inter-
vention (such as transplantation or use of immuno-
suppressive drugs) will be associated with a very
high risk of potentially life-threatening complications
and is strongly discouraged.
In a second independent oral explanation at the De-
partment of Hematology, Oncology and Rheumatology,
interested patients will have the chance to sign the in-
formed consent.
Eligible patients will then be registered for the trial.
After registration, donors will be invited for an ex-
planatory interview to ensure that the donor is fully
aware that he/she is free to decide whether to partici-
pate or not, that he/she can cancel his/her decision
to participate at any time and that there will be no
disadvantages for her/him in case of refusal. However,
it will be explained to the donor that once she/he has
successfully completed the routine work-up qualifying
for activation of the patient conditioning process for
allo-HSCT (“final donor clearance”), refusal of stem
cell donation will be associated with a very high risk
of potentially life-threatening complications for the
patient. Donors will subsequently sign the informed
consent in case of study participation.Randomization and blinding
No randomization and blinding will be part of this clinical
trial.Study intervention
After registration, patients will undergo routine work-up
for allo-HSCT (not to be reported on CRF) and should
proceed to admission for transplantation within four
weeks from enrolment. This interval may be prolonged
because of logistic (e.g. donor availability) or medical
reasons (e.g. treatment of infectious foci). Duration of
study intervention is defined as the interval from the day
before start of conditioning (d −7) and d +28 after allo-
HSCT.Conditioning
Patients will be subjected to conditioning for allo-HSCT
according to the following conditioning regimen:
Fludarabine/Cyclophosphamide
day −6 through day −2: Fludarabine 30 mg/m2/d
(=150 mg/m2 total dose)
day −3 and day −2: Cyclophosphamide 60 mg/m2/d
(=120 mg/kg total dose)
Stem cell product and stem cell transplantation
Only mobilized hematopoietic stem cells obtained from
peripheral blood by hemapheresis according to § 13
AMG and the German Transfusion Law will be used for
the purposes of this trial. The use of hematopoietic stem
cells harvested from bone marrow according to § 20 b
AMG and § 8 Transplantation Law is not allowed in this
trial.
Stem cell harvesting and production of the allograft
will be exclusively provided by the IKTZ Heidelberg
(partly using facilities of the Department of Hematology,
Oncology and Rheumatology) by standard procedures.
Fresh unmanipulated G-CSF-mobilized peripheral blood
stem cells (PBSC) obtained from the matched related
donor by standard leukapheresis are used as stem cell
source. A PBSC dose of more than 4 × 106 CD34 + cells/
kg body weight is recommended. If this target cannot be
reached by two leukapheresis procedures on consecutive
days, the transplanted cell dose will be limited to the
amount obtained at that time.
Transplantation is performed on day 0 according to
approved standard operating procedures.
GVHD prophylaxis and immune modulation
GVHD prophylaxis should be carried out with cyclospor-
ine A (CSA) and mycophenolate mofetil (CSA/MMF).
MMF treatment will then continue through day +30 and
will be discontinued without a taper if GVHD is absent.
CSA will be given from day −1 onwards.
If active GVHD is absent, CSA taper might begin from
day +60 onwards (25% of original dose every 14d). The
recommended schedules for administration of immuno-
suppressive drugs may be altered according to GVHD,
chimerism and MRD kinetics.
Donor lymphocyte infusion (DLI) is not formal part of
the study intervention but may be considered for patients
with incomplete chimerism and/or stable or increasing
MRD levels in the absence of GVHD not earlier than
4 weeks after complete withdrawal of systemic immuno-
suppression. The chimerism is tested during the indicated
follow up visits (Additional file 1: Table S1) and analyzed
by short-tandem-repeat PCR [40]. The recommended
T cell starting dose is 5x106/kg recipient weight. DLI
might be repeated every 8–12 weeks with 3-fold
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unaltered and GVHD is absent. T cells for DLI should
be obtained from the PBSC donor without prior G-CSF
mobilization by leukapheresis according to IMPD after
separate written informed consent.
Supportive measures during and after allo-HSCT will be
administered according to approved standard operating
procedures and are not part of the study intervention.Endpoints
Primary endpoint
Primary endpoint is to study if RIC allo-HSCT can provide
long-term freedom from disease recurrence with radically
resected pancreatic adenocarcinoma (measured as 2-year
progression-free survival from registration, PFS). Events
relevant for PFS are defined as clinical relapse, or death
from any cause.Secondary endpoints
Secondary efficacy endpoints are:
 2-year OS from registration;
 2-year PFS and OS after surgical resection;
 Minimal residual disease kinetics at day −28 (S),
day 0 (R), day +28 day +56,, day +100, day +180,
day +360, day + 540 and 720 days before/after
allo-HSCT (MRD; measured by tumor serum
marker levels) and their correlation with immune
events (e.g. immunosuppression tapering, GVHD);
Minimal residual disease will be measured by the
tumor marker CA 19–9. The blood sampling will be
performed routinely and the analysis will be done in
the central lab.
 Impact of important explanatory variables (such as
age, gender, comorbidity, revised R1 resection
classification score, pre-transplant tumor marker
levels, and other) on PFS and OS.
Secondary feasibility endpoints are:
 Non-relapse mortality (NRM) at 3 and 24 months
after allo-HSCT. Events relevant for NRM are
defined as death from any cause in the absence of
first disease recurrence after surgical resection;
 Prevalence of chronic graft-versus-host-disease at 6,
12 and 24 months from allo-SCT (cGVHD;
measured by NIH consensus project forms);
 Quality of life at day −28 (S) , day +28, day 56,
day +100, day +180, day +360, day +720 (end of
study) before/after allo-HSCT (QOL; measured by
EORTC QLQ C30 and HDC29);
 Impact of important explanatory variables (such as
age, gender, comorbidity, revised R1 resectionclassification score, pre-transplant tumor marker
levels, and other) on NRM.
Response evaluation
Clinical response will be determined by routine tumor
follow-up according to the RECIST criteria. Tumor
follow-up will be performed at screening, Month 3, 6,
12, 18, and 24 following routine clinical practice.
Karnofsky index and tumor marker CA19-9 will be
determined at screening, at inclusion (Day 0), on Day
28, and at each of the follow-up visits
Risks
To archive the benefit of a potential cure, the risk of the
allo-HSCT needs to be taken into account. With allo-
geneic HSCT the risk remains, that the GVHD becomes
so severe, that it cannot be controlled by immunosup-
pression. Additionally, there remains a risk of severe in-
fections. Both side effects and complications can reduce
the quality of life and can be lethal. Also pancreatic can-
cer may relapse even under allo-HSCT. The treatment
(allo-HSCT) related mortality remains under current
regimens around 10-20% within the first 24 months.
Study visits
There will be 2 pre-intervention study visits, (1) screening,
(2) registration. After the intervention 7 follow up visits
are planned on d28, d56, d100, d180, d360, d540 and
d720. The visits will asses eligibility criteria, informed
consent, HLA typing, performance scores, blood sam-
pling, abdominal CT scans, relapse evaluation, acute
and chronic GVHD evaluation, quality of life, adverse
event and serious adverse event recording. For details
see Additional file 1: Table S1.
After the end of the study or if the study finished prema-
turely, the treatment of the patient is left to the discretion
of the responsible (treating) physician and is conducted
according to medical standards. Patients will be conti-
nously monitored also after the end of the study.
Data management
All protocol-required information collected during the
trial must be entered by the investigator, or a designated
representative, in the CRF. The investigator, or the desig-
nated representative, should complete the CRF pages as
soon as possible after information is collected. Any out-
standing entries must be completed immediately after
the final examination. An explanation should be given
for all missing data. Completed CRF must be reviewed
and signed by the investigator or by a designated sub-
investigator. CRFs are sent to the Institute of Medical
Biometry and Informatics Heidelberg (IMBI) for data
entry. Copies remain at the trial site.
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CRFs correctly, the IMBI accomplishes double data entry.
The completeness, validity and plausibility of data are ex-
amined by validating programs, which thereby generate
queries. The investigator or the designated representatives
are obliged to clarify or explain the queries. At the end of
the trial, the principle investigator will retain the originals
of all CRFs.
The data will be managed and analyzed in accordance
with the appropriate SOPs valid in the IMBI.Monitoring
Monitoring will be done by personal visits from a clinical
monitor according to SOPs of the KKS (Coordination
Centre for Clinical Trials Heidelberg). The monitor will
review the entries into the CRFs on the basis of source
documents. Frequency and details of monitoring will be
defined in the monitoring manual. The investigator must
allow the monitor to verify all essential documents and
must provide support at all times to the monitor.
By frequent communications (letters, telephone, fax),
the site monitor will ensure that the trial is conducted
according to the protocol and regulatory requirements.Safety evaluation, analysis and reporting
An adverse event (AE) is any unwanted medical occur-
rence in a patient or clinical investigation subject admin-
istered a pharmaceutical or medical product and which
does not necessarily have a causal relationship with this
treatment.
A serious adverse event (SAE) is any adverse event oc-
curring at any time during the period of observation,
that results in death, is life-threatening, causes inpatient
hospitalization of prolongation of hospitalization, results
in persistent or significant disability or incapacity, leads
to a congenital anomaly or is otherwise medical relevant.
In order to investigate safety and tolerability of the
treatment, following parameters will be collected in the
course of the trial: adverse events (AEs), laboratory pa-
rameters (CBC, clinical chemistry), Clotting factors (INR
and Quick), haematology, AST, ALT, electrolytes, thyroid
value, ferritine and evaluations on acute and chronic
GVHD. Furthermore, the continuing monitoring of safety
of the enrolled subjects will be assured by collecting and
processing of serious adverse events (SAEs). So as to ob-
tain an independent expert opinion a Data Monitoring
and Safety Committee (DSMC) will be appointed.
All AEs will be carefully documented on the appropriate
pages in the CRF. Undesirable signs, symptoms or medical
conditions/diseases present before starting study treat-
ment are only to be documented if they worsen after start-
ing study treatment. The start date for AEs that were
present at the study start and that worsen during the studyshould be reported as the date the events worsened, not
the date the events began pre-study.
Only SAEs should be reported and – on separate
forms – any symptoms or signs of acute or chronic
GVHD even if not fulfilling the criteria of SAE. SAEs
will be documented up to the last trial visit, i.e. up to
24 months after trial inclusion.
However, certain adverse events are a mandatory con-
sequence of the conditioning regimen administered prior
to allo-HSCT. Therefore any changes in blood counts
and differential between days −7 and +28 will be moni-
tored and captured by CRF but should not be recorded
additionally as AE.
If an SAE occurs, the investigator completes the SAE
report form. The form has to be sent (by fax) to the
Trial Pharmacovigilance Office within 24 hours.
The Trial Pharmacovigilance Office notifies the Paul-
Ehrlich-Institute (reports to the Federal Ministry of
Health), the Ethics Committee and the PI of any SUSAR
according to the prevailing regulations.Data Monitoring and Safety Committee (DMSC)
An independent Data Monitoring and Safety Committee
(DMSC) has been set up in accordance with the European
“Guideline on Data Monitoring Committees” (EMEA/
CHMP/EWP/5872/03 Corr).
The DMSC consists of three independent members,
who will not be involved in the trial. One is a senior bio-
statistician, one is an expert in surgical RCTs and one is
an expert in medical RCTs. All have served already on
DMSCs. At pre-specified time-points, namely after enroll-
ment and day +100, assessment of the first and second pa-
tient cohorts of 3 patients each, respectively, the DMSC
will evaluate 100-day NRM and SAE status. Based on
the results of these two safety evaluations, the DMSC
will recommend continuation, interruption, amendment
or termination of the trial. In addition, the DMSC may
recommend interruption of the trial at any time if safety
concerns arise upon SAE evaluation or due to other
reasons.Statistical analysis
The primary and secondary outcomes will be analyzed
applying methods of descriptive data analysis.
For the primary endpoint, 2-year progression-free sur-
vival after surgical resection, the Kaplan-Meier estimate
and the corresponding two-sided 90% Greenwood confi-
dence interval based on a log(−log)-transformation [31]
are calculated. The primary analysis is performed based
on the full analysis set; to assess the impact of major
protocol deviations, the analyses of the primary endpoint
described above will also be performed for the per
protocol set.
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will be performed analogously to the primary endpoint.
Furthermore, all documented variables will be analyzed
descriptively by tabulation of the measures of the em-
pirical distributions. According to the scale level of the
variables, mean, standard deviations, median, 1st and 3rd
quartile, as well as minimum and maximum or absolute
and relative frequencies, respectively, will be reported.
Additionally, for variables with longitudinal measure-
ments the time course of individual patients will be
depicted. Descriptive p-values of the corresponding
statistical tests comparing baseline and follow-up mea-
surements and associated 95% confidence intervals will
be given.
Safety analysis will be based on the data set of all pa-
tients who were treated within the trial. The safety analysis
includes calculation of frequencies and rates of reported
adverse and serious adverse events.
An important part of the analysis comprises the com-
parison of the results of this trial with historical data
available for the patient population under consideration.
At the timepoint of the analysis, a systematic review will
be performed providing the up-to-date evidence on effi-
cacy and safety of alternative therapies.
All analyses will be done using SAS version 9.1 or
higher.Funding
Heidelberg Surgery Foundation, University of Heidelberg,
Im Neuenheimer Feld 110, D-69120 Heidelberg, Tel: (49)
06221/ 56 4875, Fax: (49) 06221/56 4877, stiftung.chirur-
gie@med.uni-heidelberg.de, www.stiftung-chirurgie.com.Ethical and legal consideration
Approval
In accordance with the Declaration of Helsinki, the German
Drug Law (Arzneimittelgesetz [AMG]), the German Good
Clinical Practice ordinance (GCP-V), and the Note for
Guidance on Good Clinical Practice (GCP) [39], the study
was presented to the independent Medical Ethics Com-
mittee of the University of Heidelberg (EC) and the
Paul-Ehrlich-Institute (PEI), as competent authority. The
approval of the EC and the authorization of the PEI will
be obtained prior to any study-related procedures.
Any substantial change in the clinical study protocol
and any change in the informed consent form (§ 10 and
§ 11 GCP-V) will be presented to the EC and any sub-
stantial change in the clinical study protocol to the PEI.
Substantial amendments have to be approved by them
before implementation (except to eliminate immediate
hazards).
The EC and the PEI will be informed about the end of
the study (§ 13 GCP-Verordnung).Patient informed consent
According to AMG, GCP-V, and the Note for Guidance
on GCP [39], written informed consent must be obtained
from patients prior to participation in the study.
Patients and donors will voluntarily and separately
confirm their willingness to participate in the study, after
having been informed by separate physicians in writing
and verbally of all aspects of the study that are relevant
to their decision to participate. They will be informed
about requirements concerning data protection and have
to agree to the direct access to their individual data.
Patients will be informed that they are free to withdraw
from the study at any time at their own discretion without
necessarily giving reasons.
Good clinical practice and other legal basis
The study will be carried out in conformity with the
principals of the Declaration of Helsinki and the Guide-
lines for Good Clinical Practice in their current revisions.
The trial will be carried out in keeping with national and




The STEM PACE study aims to generate state-of-the-art
scientific clinical evidence that reduced intensity allo-
HSCT is feasible in patients with effectively resected
pancreatic adenocarcinoma and, further, that it can pro-
vide long-term disease control. This approach is aimed
to elucidate if allo-HSCT under conditions with minimal
residual disease may have the potential to change the
natural course of this, even with modern chemotherapy
regimens, otherwise mostly fatal disease. Due to the
severe side effects of allo-HSCT, including high levels of
treatment related mortality in the patients, this therapy
option was up to now mainly explored in patients with
refractory and far advanced solid tumors. Even though
some of the results from previous studies were promising
with objective tumor response in refractory disease set-
tings, treatment of solid tumors with allo-HSCT remains
in a niche.
The STEM PACE study will evaluate the role of allo-
HSCT using a novel approach in solid tumors. To cir-
cumvent the treatment related mortality of standard
myeloablative regimens we will apply a non-myeloablative
reduced-intensity conditioning regimen. This use of non-
myeloablative conditioning does therefore not rely on
chemotherapy related cytoreduction administered before
transplant but rather on the immune effect of the
grafted stem cells. Non-myeloablative conditioning be-
fore allogenic transplantation can archive full myeloid
and lymphoid chimarism leading to anti-tumor activity
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tality [18,41,42]. Using this technique, the study will rely
on the immune graft-versus-tumor effect of the allo-
HSCT. This effect is well described in hematological
diseases in which patients with graft-versus-host disease
have a lower probability of relapse than patients with-
out. Additional donor lymphocyte infusions were able
to successfully induce remission in relapsed patients
without additional cytotoxic therapy after allo-HSCT
[36]. Although it is not well investigated to which extent
the pancreas is a target organ for chronic GVHD or po-
tential GvT, preliminary evidence suggests the pancreatic
gland might be affected by acute or chronic GVHD
[43,44]. Moreover, it is well acknowledged that the bio-
logically closely related salivary glands are a prime target
organ for chronic GVHD prone to complete destruction
by GVHD-mediated inflammation [45].
However, it needs to be taken into account that in previ-
ous studies a high proportion of patients who underwent
allo-HSCT in solid tumors progressed rapidly due to the
high initial tumor burden. As described above, effective
GvT-mediated disease control after allo-HSCT correlates
with tumor mass and proliferation at the time of trans-
plant [36-38]. This remains a special problem in pancre-
atic cancer as a fast progressing tumor. To overcome this
limitation we will only include patients who have under-
gone surgery and adjuvant chemotherapy, leading to a
minimal residual disease setting. Under these conditions
we hope to achieve a full chimarism and GVT before
relapse of the disease. This might give the opportunity
to eliminate remaining tumor cells, which will otherwise
most likely lead to recurrence of the tumor. Transplant-
ation after surgery with subsequent chemotherapy will
additionally allow the chance to select patients with at
least stable disease, therefore identifying a more suitable
patient population who might profit from this treatment.
This is of special importance since it was published before
that out of 116 patients with different solid tumors
response to allo-HSCT was strongly correlated to stable
disease, while only 1 out of 52 patients with progressive
disease showed a clinical response [23].
The strong stromal reaction of pancreatic cancer might
pose an additional problem for allo-HSCT in advanced
pancreatic cancer, which will be bypassed by surgical
tumor removal. This should be taken into account,
since in leukemias the stromal microenvironment acts
in a protective manner to malignant cells by different
mechanisms [46-48]. By interaction with the microenvir-
onment, hematopoietic tumor cells persisting at extrame-
dullary sites seem to less sensitive to GvT effects [36,49].
The role of allo-HSCT in pancreatic cancer was previ-
ously studied [29-31], however, all previous studies were
only done in relatively small cohorts. This phase II study
will provide the opportunity to establish a clearer pictureon the role of allo-HSCT in pancreatic cancer. As only
fully HLA-matched directly related sibling donors will
be included into this trial it will be possible to compare
the outcome of this study with a non-randomized con-
trol group without undergoing a positive selection bias.
The selection and recording of the primary and second-
ary endpoints will allow further phase II or III studies in
the future in case of promising results. With the focus
on a single center the standardized surgical procedures
as well as the pathological evaluation will be comparable
at this phase of clinical trials. The pathologic postoperative
evaluation is of importance in pancreatic cancer, as the
tumor infiltration of the resection margin, the R status,
is especially difficult to distinguish and often wrongly
assessed as a R0 resection [50].
To discuss the ethical implications of treating surgically
resected patients after chemotherapy with an allo-HSCT,
the overall survival of pancreatic cancer patients needs to
be taken into account. Even patients who have undergone
the best current treatment with complete surgical resec-
tion and adjuvant chemotherapy only achieve a median
survival of about 24 months [5,8,9]. This unfavorable out-
come asks for further alternative treatment options [51].
On the other hand, using allo-HSCT as an additional
treatment is accompanied with a risk of severe infections.
Further, the risk remains, that the GVHD becomes so se-
vere, that it cannot be controlled by immunosuppression.
Both side effects and complications can reduce the quality
of life and can be lethal. Treatment related mortality of
allo-HSCT remains under current regimens around 10-
20% within the first 24 months. Last but not least pancre-
atic cancer may relapse even under allo-HSCT. To take
these treatment related risks into account we exclude pa-
tients with a high 5-year overall survival probability and
pre-select patients with an average 5 year survival of below
20%. However this will need to be openly discussed with
the patients additional to the patient information forms.
In summary, allo-HSCT however risky, may provide po-
tentially a chance to permanently cure or suppress pancre-
atic cancer. While 50% of all patients using the current
available treatment will die within 2 years, allo-HSCT will
lead to about 10-20% treatment related lethality in the pa-
tients and about the same amount of patients will have a
reduced quality of life due to treatment related side effects
(GvHD). In summary, we hope this treatment may offer a
chance to eradicate persisting tumor cells in this otherwise
lethal disease.
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